ReviewBiology2020
Organismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease.
Review in Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Fructose Diet-Induced Liver Injury Through Oxidative Stress: A Systematic Review of Preclinical Studies.Journal of nutrition and metabolism · 2026Review
- Pharmacophore-based virtual screening andFrontiers in pharmacology · 2025Article
- Gut microbes, diet, and genetics as drivers of metabolic liver disease: a narrative review outlining implications for precision medicine.The Journal of nutritional biochemistry · 2024Review
- Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians:International journal of molecular sciences · 2024Article
- The Good, the Bad and the New about Uric Acid in Cancer.Cancers · 2022Review
- Crosstalk between TM4SF5 and GLUT8 regulates fructose metabolism in hepatic steatosis.Molecular metabolism · 2022Article
- Review
- Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19.World journal of clinical cases · 2021Review
- The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
NAFLD has alarmingly increased, yet FDA-approved drugs are still lacking. An excessive intake of fructose, especially in liquid form, is a dietary risk factor of NAFLD. While fructose metabolism has been studied for decades, it is still controversial how fructose intake can cause NAFLD. It has long been believed that fructose metabolism solely happens in the liver and accordingly, numerous studies have investigated liver fructose metabolism using primary hepatocytes or liver cell lines in culture. While cultured cells are useful for studying detailed signaling pathways and metabolism in a cell-autonomous manner, it is equally important to understand fructose metabolism at the whole-body level in live organisms. In this regard, recent in vivo studies using genetically modified mice and stable isotope tracing have tremendously expanded our understanding of the complex interaction between fructose-catabolizing organs and gut microbiota. Here, we discuss how the aberrant distribution of fructose metabolism between organs and gut microbiota can contribute to NAFLD. We also address potential therapeutic interventions of fructose-elicited NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.